Protein Engineering Global Market Report 2024

The global protein engineering market has grown rapidly in recent years. It will grow from $3.63 billion in 2023 to $4.14 billion in 2024 at a compound annual growth rate (CAGR) of 14.2%. The growth observed in the historical period in the field of protein engineering can be attributed to various factors, including scientific breakthroughs, early therapeutic success stories, the biopharmaceutical revolution, the emergence of monoclonal antibodies, and the establishment of regulatory frameworks. These factors collectively contributed to the development and expansion of protein engineering during the specified historical period.

The global protein engineering market is expected to see rapid growth in the next few years. It will grow to $7.2 billion in 2028 at a compound annual growth rate (CAGR) of 14.8%. The anticipated growth in the forecast period for protein engineering can be attributed to factors such as the increasing demand for therapeutic proteins, advancements in biotechnology, ongoing developments in drug research and development, the rising prevalence of chronic diseases, and a heightened focus on precision medicine. Major trends expected in the forecast period include the utilization of advanced protein design tools, the application of high-throughput screening techniques, the integration of artificial intelligence (AI) and machine learning, the adoption of novel protein expression systems, and the use of CRISPR and gene editing technologies. These trends reflect the continuous evolution and innovation within the field of protein engineering to meet the demands of healthcare and biotechnological advancements.

The escalating demand for protein-based drugs is a key driver fueling the growth of the protein engineering market. These drugs, derived from proteins and utilized for therapeutic purposes, are genetically engineered versions of naturally occurring human proteins. Protein engineering techniques involve modifying protein sequences by altering nucleotides within their encoding genes. This alteration aims to tailor protein-based drugs to specific applications, optimizing their effectiveness. For instance, a study published in the Lancet Diabetes and Endocrinology journal forecasts a 20% increase, reaching nearly 80 million individuals requiring insulin for type-2 diabetes by 2030. This burgeoning demand underscores the impetus driving the protein engineering market.

The surge in the prevalence of chronic diseases stands as a driving force behind the growth trajectory of the protein engineering market. Chronic diseases, persisting over extended periods, present challenges for effective treatment. Protein engineering plays a pivotal role in developing targeted therapies by customizing treatments for precision drug design. This approach enhances specificity, minimizes side effects, and introduces innovative personalized medication options. With complex molecular mechanisms often involved in chronic illnesses, the ability to customize drugs through protein engineering becomes crucial in addressing specific disease pathways. According to the National Center for Biotechnology Information (NCBI), the global population affected by chronic diseases is projected to escalate to 142.66 million by 2050 from 71.522 million in 2020, emphasizing the driving force of protein engineering in combating chronic diseases.

Leading companies in protein engineering are prioritizing the establishment of advanced protein engineering foundries, catering to improved research and industrial applications. These foundries function as comprehensive protein engineering laboratories, enabling swift and scaled testing of new proteins across various technologies. For example, Adaptyv Bio, a Switzerland-based advanced nanotechnology and biotechnology company, introduced a protein engineering foundry in April 2023. This integrated laboratory empowers protein engineers to efficiently iterate designs and collect data on proteins, significantly reducing reagent usage, experiment duration, and cost per data point. The integration of artificial intelligence (AI) across all stages of protein creation, from sequence design to experimental execution and data recording, aims to democratize protein design research and accelerate the field of protein engineering. The ultimate goal is to streamline protein engineering processes for enhanced accessibility and rapid advancements.

Major players in the protein engineering market are actively innovating by introducing novel gene therapy solutions to establish a competitive edge. In July 2021, Integral Molecular, a biotechnology company based in the US, launched GeneCanvas, a proprietary protein engineering platform tailored for optimizing transgenes and associated elements utilized in gene therapy. GeneCanvas focuses on significantly enhancing gene activity by improving transgene protein expression, trafficking, stability, and function. This advancement holds promise in elevating the effectiveness of gene therapies, potentially enabling the administration of smaller doses while bolstering patient safety. Leveraging Integral Molecular's proprietary high-throughput mutagenesis and human cell screening technologies, the platform enables the creation and screening of extensive variant libraries. This approach allows a customized solution to diverse engineering challenges encountered in gene therapy.

In July 2021, Eli Lilly and Company, a renowned pharmaceutical entity based in the US, completed the acquisition of Protomer Technologies for a transaction exceeding $1 billion. This strategic move grants Lilly access to Protomer's cutting-edge engineering platform, specifically designed to identify and synthesize molecules capable of sensing glucose or other endogenous regulators of protein activity. Protomer Technologies specializes in advanced protein therapies that have the unique ability to sense molecular activators within the human body, offering significant potential in the realm of therapeutic interventions leveraging protein engineering. This acquisition further reinforces Lilly's pursuit of pioneering protein-based therapeutic solutions by incorporating Protomer's innovative capabilities into its research and development endeavors.

Major companies operating in the protein engineering market report are Bruker Corporation, Codexis Inc., Danaher Corporation, Thermo Fisher Scientific Inc., GenScript Biotech Corporation, Agilent Technologies Inc., Bio-Rad Laboratories Inc., New England Biolabs Inc., PerkinElmer Inc., Amgen Inc., InvivoGen, Enantis s.r.o., Promega Corporation, Merck KGaA, Aragen Bioscience Inc., Creative BioMart, Waters Corporation, Genentech Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., GlaxoSmithKline PLC, Johnson & Johnson, Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Biogen Inc., Abzena plc.

North America was the largest region in the protein engineering market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein engineering market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the protein engineering market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products and services in protein engineering encompass instruments, reagents, services, and software. Instruments are tools or devices used for scientific tasks related to protein engineering, leading to alterations in the protein backbone. The proteins involved in this process include insulin, monoclonal antibodies, coagulation factors, vaccines, growth factors, and others. The technologies utilized include irrational protein design and rational protein design. Protein engineering finds applications in pharmaceutical and biotechnology companies, academic research institutes, and contract research organizations.

This report provides protein engineering market statistics, including protein engineering industry global market size, regional shares, competitors with an protein engineering market share, detailed protein engineering market segments, market trends and opportunities, and any further data you may need to thrive in the protein engineering industry. This protein engineering market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The protein engineering market consists of revenues earned by entities by providing protein engineering services through use of enzymes, interleukins, and thrombolytics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.